The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Open accessAbstract
BACKGROUND: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study. METHODS: We randomly assigned 418 previously untreated patients who had metastatic melanoma without a BRAF mutation to receive nivolumab (at a dose of 3 mg per kilogram of body weight every 2 weeks and dacarbazine-matched placebo every 3 weeks) or dacarbazine (at a dose of 1000 mg per square meter of body-surface area every 3 weeks and nivolumab-matched placebo every 2 weeks). The primary end point was overall survival. RESULTS: At 1 year, the overall rate of survival was 72.9% (95% confidence interval [CI], 65.5 to 78.9) in the nivolumab group, as compared with 42.1% (95% CI, 33.0 to 50.9) in the dacarbazine group (hazard ratio for death, 0.42; 99.79% CI, 0.25 to 0.73; P<0.001). The median progression-free survival was 5.1 months in the nivolumab group versus 2.2 months in the dacarbazine group (hazard ratio for death or progression of disease, 0.43; 95% CI, 0.34 to 0.56; P<0.001). The objective response rate was 40.0% (95% CI, 33.3 to 47.0) in the nivolumab group versus 13.9% (95% CI, 9.5 to 19.4) in the dacarbazine group (odds ratio, 4.06; P<0.001). The survival benefit with nivolumab versus dacarbazine was observed across prespecified subgroups, including subgroups defined by status regarding the programmed death ligand 1 (PD-L1). Common adverse events associated with nivolumab included fatigue, pruritus, and nausea. Drug-related adverse events of grade 3 or 4 occurred in 11.7% of the patients treated with nivolumab and 17.6% of those treated with dacarbazine. CONCLUSIONS: Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation. (Funded by Bristol-Myers Squibb; CheckMate 066 ClinicalTrials.gov number, NCT01721772.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“however responses to these therapies are often heterogeneous and not durable (1–3).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [3]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with immunotherapy targeting checkpoint inhibitors PD-1 or CTLA-4 significantly increases survival in patients with metastatic melanoma over other standards of care [1, 2]”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While immune checkpoint inhibitors (ICIs) have greatly enhanced clinical outcomes across multiple cancer types,1, 2, 3”
From irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, the responses to ICI treatment have still been observed in those with low or undetectable levels of PD-L1 expression.9”
From The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC (2019) · cites this paper as [9]
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [3]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationHauschild, A., Grob, J., Демидов, Л. В., Jouary, T., Gutzmer, R., Millward, M. J., Rutkowski, P. L., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 3,050
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
Self-citationSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1200/JCO.2013.51.4802 · DOI · Paper page
Cited by
Sorted by citations
Items 701–800 of 1,032
Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases
Naran, K., Nundalall, T., Chetty, S., & Barth, S. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03158 · Cited by 128
Immune checkpoint inhibitors win the 2018 Nobel Prize
Huang, P., & Chang, J. W. (2019) · Biomedical Journal · doi:10.1016/j.bj.2019.09.002 · Cited by 130
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 122
Najjar, Y. G., Navrazhina, K., Ding, F., Bhatia, R., Tsai, K. K., Abbate, K. T., Durden, B., Eroglu, Z., Bhatia, S., Park, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000331 · Cited by 122
Yang, F., Markovic, S. N., Molina, J. R., Halfdanarson, T. R., Pagliaro, L. C., Chintakuntlawar, A. V., Li, R., Wei, J., Wang, L., Liu, B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.12534 · Cited by 124
Papavassiliou, A. G., & Musti, A. M. (2020) · Cells · doi:10.3390/cells9112470 · Cited by 124
Kim, R., Kwon, M., An, M., Kim, S. T., Smith, S. A., Loembé, A., Mortimer, P. G. S., Armenia, J., Lukashchuk, N., Shah, N., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.10.009 · Cited by 124
Queirolo, P., & Spagnolo, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.002 · Cited by 121
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0541-9 · Cited by 122
Seremet, T., Jansen, Y. J. L., Planken, S., Njimi, H., Delaunoy, M., Housni, H. E., Awada, G., Schwarze, J. K., Keyaerts, M., Everaert, H., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2051-8 · Cited by 126
Ritchie, G. E., Gasper, H. M., Man, J., Lord, S. J., Marschner, I. C., Friedlander, M. L., & Lee, C. K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5236 · Cited by 121
Queirolo, P., Boutros, A., Tanda, E. T., Spagnolo, F., & Quaglino, P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.001 · Cited by 120
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Wang, X., Wang, F., Zhong, M., Yarden, Y., & Fu, L. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01200-x · Cited by 124
Kostine, M., Cleven, A. H. G., de Miranda, N. F. C. C., Italiano, A., Cleton-Jansen, A., & Bovée, J. V. M. G. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.108 · Cited by 125
Relevance of randomised controlled trials in oncology
Tannock, I. F., Amir, E., Booth, C. M., Niraula, S., Ocaña, A., Šeruga, B., Templeton, A. J., & Vera-Badillo, F. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30572-1 · Cited by 121
Tay, R. Y., Blackley, E., McLean, C., Moore, M., Bergin, P., Gill, S., & Haydon, A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.253 · Cited by 119
Recent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 119
T‐Cell‐Mimicking Nanoparticles for Cancer Immunotherapy
Kang, M., Hong, J., Jung, M., Kwon, S. P., Song, S. Y., Kim, H. Y., Lee, J., Kang, S., Han, J., Koo, J., et al. (2020) · Advanced Materials · doi:10.1002/adma.202003368 · Cited by 119
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
Jia, X., Geng, L., Jiang, P., Xu, H., Nan, K., Yao, Y., Jiang, L., Sun, H., Qin, T., & Guo, H. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01749-x · Cited by 120
Boku, N., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H. C., Chen, J., Muro, K., Kang, W. K., Yeh, K., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01173-w · Cited by 119
Wang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 131
Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma
Calapre, L., Warburton, L., Millward, M., Ziman, M., & Gray, E. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.030 · Cited by 118
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mößner, R., Ugurel, S., Zimmer, L., & Gutzmer, R. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047 · Cited by 120
Self-citationLong, G. V., Atkinson, V. G., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P. L., Savage, K. J. J., Taylor, F. C., Coon, C. D., Gilloteau, I., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw265 · Cited by 118
Self-citationFine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome
Pitt, J. M., Vétizou, M., Waldschmitt, N., Kroemer, G., Chamaillard, M., Boneca, I. G., & Zitvogel, L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0448 · Cited by 122
George, J., Bajaj, D., Sankaramangalam, K. P., Yoo, J. W., Joshi, N. S., Gettinger, S. N., Price, C. C., & Farrell, J. J. (2019) · Pancreatology · doi:10.1016/j.pan.2019.04.015 · Cited by 118
Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56
Zou, F., Lu, L., Liu, J., Xia, B., Zhang, W., Hu, Q., Liu, W., Zhang, Y., Lin, Y., Jing, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11893-4 · Cited by 120
Zhu, B., Tang, L., Chen, S., Yin, C., Peng, S., Li, X., Liu, T., Liu, W., Han, C., Stawski, L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0314-0 · Cited by 117
Shien, K., Papadimitrakopoulou, V. A., & Wistuba, I. I. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.016 · Cited by 119
Chesney, J. A., Mitchell, R. A., & Yaddanapudi, K. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1116-458rrr · Cited by 120
The Future of Immune Checkpoint Cancer Therapy After PD-1 and CTLA-4
Hahn, A. W., Gill, D. M., Pal, S. K., & Agarwal, N. (2017) · Immunotherapy · doi:10.2217/imt-2017-0024 · Cited by 119
Gatalica, Z., Xiu, J., Swensen, J. J., & Vranić, S. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.021 · Cited by 118
Correlation between sex and efficacy of immune checkpoint inhibitors ( PD ‐1 and CTLA ‐4 inhibitors)
Wu, Y. C., Ju, Q., Jia, K., Yu, J., Shi, H. M., Wu, H., & Jiang, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31301 · Cited by 118
Coghill, A. E., Han, X., Suneja, G., Lin, C. C., Jemal, A., & Shiels, M. S. (2019) · Cancer · doi:10.1002/cncr.32158 · Cited by 117
Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma
Chang, C., Park, H., Malone, D. C., Wang, C.-Y., Wilson, D. L., Yeh, Y., van Boemmel-Wegmann, S., & Lo-Ciganic, W.-H. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.1611 · Cited by 119
Cancer biomarkers for targeted therapy
Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0178-7 · Cited by 118
Ali, O. H., Diem, S., Markert, E., Jochum, W., Kerl, K., French, L. E., Speiser, D. E., Früh, M., & Flatz, L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1231292 · Cited by 117
Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?
Rosenblatt, J. M., & Avigan, D. (2016) · Blood · doi:10.1182/blood-2016-08-731885 · Cited by 117
Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
Wu, R.-Y., Kong, P., Xia, L.-P., Huang, Y., Li, Z., Tang, Y.-Y., Chen, Y.-H., Li, X., Senthilkumar, R., Zhang, H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2840 · Cited by 116
Klümper, N., Ralser, D. J., Bawden, E., Landsberg, J., Zarbl, R., Kristiansen, G., Toma, M. I., Ritter, M., Hölzel, M., Ellinger, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000552 · Cited by 116
Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy
Morelli, T., Fujita, K., Redelman‐Sidi, G., & Elkington, P. T. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217260 · Cited by 116
PD-L1 expression as a potential predictive biomarker
Fusi, A., Festino, L., Botti, G., Masucci, G. V., Melero, I., Lorigan, P. C., & Ascierto, P. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00307-1 · Cited by 117
Self-citationRoszik, J., Haydu, L. E., Hess, K. R., Oba, J., Joon, A. Y., Siroy, A. E., Karpinets, T. V., Stingo, F. C., Baladandayuthapani, V., Tetzlaff, M. T., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0705-4 · Cited by 115
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 117
Nishino, M., Ramaiya, N. H., Chambers, E. S., Adeni, A. E., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0193-2 · Cited by 117
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
Audrito, V., Serra, S., Stingi, A., Orso, F., Gaudino, F., Bologna, C., Neri, F., Garaffo, G., Nassini, R., Baroni, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15213 · Cited by 118
Multiple sclerosis outcomes after cancer immunotherapy
García, C. R., Jayswal, R. D., Adams, V. R., Anthony, L. B., & Villano, J. L. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02060-8 · Cited by 117
PD-L1 testing by immunohistochemistry in immuno-oncology
Vranić, S., & Gatalica, Z. (2022) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2022.7953 · Cited by 120
Noncoding RNA s and immune checkpoints—clinical implications as cancer therapeutics
Smolle, M. A., Calin, H. N., Pichler, M., & Călin, G. A. (2017) · FEBS Journal · doi:10.1111/febs.14030 · Cited by 114
Tetzlaff, M. T., Nagarajan, P., Chon, S. Y., Huen, A., Diab, A. K., Pacha, O., Aung, P. P., Torres-Cabala, C. A., Mays, S. R., Prieto, V. G., et al. (2017) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000688 · Cited by 116
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma
Müller, T., Braun, M., Dietrich, D., Aktekin, S., Höft, S., Kristiansen, G., Göke, F., Schröck, A., Brägelmann, J., Held, S. A. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17547 · Cited by 119
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 115
Rosato, R. R., Dávila‐González, D., Choi, D. S., Qian, W. P., Chen, W., Kozielski, A. J., Wong, H. H., Dave, B., & Chang, J. C. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1037-4 · Cited by 115
Nakamura, Y., Tanaka, R., Maruyama, H., Ishitsuka, Y., Okiyama, N., Watanabe, R., Fujimoto, M., & Fujisawa, Y. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy201 · Cited by 114
Li, Y., He, M., Zhou, Y., Yang, C., Wei, S., Bian, X., Christopher, O., & Xie, L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00139 · Cited by 119
The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities
Silver, D. J., Sinyuk, M., Vogelbaum, M. A., Ahluwalia, M. S., & Lathia, J. D. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov157 · Cited by 114
Katoh, Y., Yaguchi, T., Kubo, A., Iwata, T., Morii, K., Kato, D., Ohta, S., Satomi, R., Yamamoto, Y., Oyamada, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004616 · Cited by 115
Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy
Joshi, D. C., Sharma, A., Prasad, S., Singh, K., Kumar, M., Sherawat, K., Tuli, H. S., & Gupta, M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01195-7 · Cited by 119
Morse, M. A., Overman, M. J., Hartman, L., Khoukaz, T., Brutcher, E., Lenz, H.-J., Atasoy, A., Shangguan, T., Zhao, H., & El-Rayes, B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0129 · Cited by 112
Harnessing the immune system in acute myeloid leukaemia
Austin, R. J., Smyth, M. J., & Lane, S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.04.020 · Cited by 114
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, P. I., & Antonarakis, E. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1464388 · Cited by 114
Kraman, M., Faroudi, M., Allen, N. L., Kmiecik, K., Gliddon, D., Seal, C. J., Koers, A., Wydro, M. M., Batey, S., Winnewisser, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3548 · Cited by 113
Tumor metastasis: Mechanistic insights and therapeutic interventions
Liu, M., Yang, J., Xu, B.-S., & Zhang, X. (2021) · MedComm · doi:10.1002/mco2.100 · Cited by 124
Shi, L. Z., Fu, T., Guan, B., Chen, J., Blando, J. M., Allison, J. P., Xiong, L., Subudhi, S. K., Gao, J., & Sharma, P. (2016) · Nature Communications · doi:10.1038/ncomms12335 · Cited by 111
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Botticelli, A., Onesti, C. E., Zizzari, I. G., Cerbelli, B., Sciattella, P., Occhipinti, M. A., Roberto, M., Pietro, F. R. D., Bonifacino, A., Ghidini, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22242 · Cited by 113
Grassadonia, A., Sperduti, I., Vici, P., Iezzi, L., Brocco, D., Gamucci, T., Pizzuti, L., Maugeri‐Saccà, M., Marchetti, P., Cognetti, G., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120542 · Cited by 112
The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy
Yuan, W., Zhao, Q., Gao, Z., Lao, X., Lin, W., Chen, D., Mu, M., Huang, C.-X., Liu, Z., Li, B., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127726 · Cited by 114
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Cadranel, J. L., Canellas, A., Matton, L., Darrason, M., Parrot, A., Naccache, J., Lavolé, A., Ruppert, A.-M., & Fallet, V. (2019) · European Respiratory Review · doi:10.1183/16000617.0058-2019 · Cited by 113
Ugurel, S., Röhmel, J., Ascierto, P. A., Becker, J. C., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Livingstone, E., Long, G. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.021 · Cited by 114
Self-citationFrom bench to bedside a comprehensive review of pancreatic cancer immunotherapy
Kunk, P. R., Bauer, T. W., Slingluff, C. L., & Rahma, O. E. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0119-z · Cited by 110
The use of pembrolizumab for the treatment of metastatic uveal melanoma
Kottschade, L. A., McWilliams, R. R., Markovic, S. N., Block, M. S., Villasboas, J. C., Pham, A., Esplin, B. L., & Dronca, R. S. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000242 · Cited by 111
Toxicity management of immunotherapy for patients with metastatic melanoma
Linardou, H., & Gogas, H. J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.07.10 · Cited by 112
Self-citationCheckpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
Mittica, G., Ghisoni, E., Giannone, G., Aglietta, M., Genta, S., & Valabrega, G. (2017) · Oncotarget · doi:10.18632/oncotarget.20042 · Cited by 113
Mollaei, M., Hassan, Z. M., Khorshidi, F., & Langroudi, L. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101056 · Cited by 114
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 113
Next-generation combination approaches for immune checkpoint therapy
Goswami, S., Pauken, K. E., Wang, L., & Sharma, P. (2024) · Nature Immunology · doi:10.1038/s41590-024-02015-4 · Cited by 114
Kosmides, A. K., Meyer, R. A., Hickey, J. W., Aje, K., Cheung, K. N., Green, J. J., & Schneck, J. P. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.038 · Cited by 109
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
Bartee, M. Y., Dunlap, K. M., & Bartee, E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1638 · Cited by 111
Huffman, B. M., Kottschade, L. A., Kamath, P. S., & Markovic, S. N. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000374 · Cited by 100
Berger, K., & Pu, J. J. (2017) · Gene · doi:10.1016/j.gene.2017.09.050 · Cited by 113
Shi, G., Yang, Q., Zhang, Y., Jiang, Q., Lin, Y., Yang, S., Wang, H., Cheng, L., Zhang, X., Li, Y., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.010 · Cited by 112
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
Onoyama, T., Takeda, Y., Yamashita, T., Hamamoto, W., Sakamoto, Y., Koda, H., Kawata, S., Matsumoto, K., & Isomoto, H. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i3.353 · Cited by 110
Cost-Effectiveness of Immune Checkpoint Inhibition inBRAFWild-Type Advanced Melanoma
Kohn, C. G., Zeichner, S. B., Chen, Q., Montero, A. J., Goldstein, D. A., & Flowers, C. R. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.6336 · Cited by 110
Feng, Y., Wang, X., Bajaj, G., Agrawal, S., Bello, A., Lestini, B. J., Finckenstein, F. G., Park, J.-S., & Roy, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2842 · Cited by 109
Global mapping of cancers: The Cancer Genome Atlas and beyond
Ganini, C., Amelio, I., Bertolo, R. G., Bove, P., Buonomo, O. C., Candi, E., Cipriani, C., Daniele, N. D., Juhl, H. H., Mauriello, A., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13056 · Cited by 110
Towards a consensus definition of immune exclusion in cancer
Tiwari, A., Oravecz, T., Dillon, L. A. L., Italiano, A., Audoly, L., Fridman, W. H., & Clifton, G. T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1084887 · Cited by 117
Bai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107
Autoimmune endocrine dysfunctions associated with cancer immunotherapies
Ferrari, S. M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M. R., Baldini, E., Ulisse, S., Marone, G., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102560 · Cited by 107
The changing landscape of phase I trials in oncology
Wong, K. M., Capasso, A., & Eckhardt, S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.194 · Cited by 110
The use of immunotherapy in the treatment of melanoma
Achkar, T., & Tarhini, A. A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0458-3 · Cited by 110
Broos, K., Lecocq, Q., Raes, G., Devoogdt, N., Keyaerts, M., & Breckpot, K. (2018) · Theranostics · doi:10.7150/thno.24762 · Cited by 108
Tostivint, E. P., Latouche, A., Vaflard, P., Ricci, F., Loirat, D., Hescot, S., Sablin, M., Rouzier, R., Kamal, M. T., Morel, C., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00114 · Cited by 112
Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options
Kohoutová, D., Worku, D. A., Aziz, H., TEARE, J. P., Weir, J., & Larkin, J. (2021) · Cells · doi:10.3390/cells10020327 · Cited by 111
Zhu, Z., Liu, W., & Gotlieb, V. K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.002 · Cited by 109
Combinatorial approach to cancer immunotherapy: strength in numbers
Vilgelm, A. E., Johnson, D. B., & Richmond, A. J. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 109
Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review
Jhaveri, K. D., Wanchoo, R., Sakhiya, V., Ross, D. W., & Fishbane, S. N. (2016) · Kidney International Reports · doi:10.1016/j.ekir.2016.09.055 · Cited by 106
Alva, A. S., Daniels, G. A., Wong, M. K., Kaufman, H. L., Morse, M. A., McDermott, D. F., Clark, J. I., Agarwala, S. S., Miletello, G. P., Logan, T. F., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1910-x · Cited by 109
Choong, E. S., Lo, S., Drummond, M., Fogarty, G. B., Menzies, A. M., Guminski, A. D., Shivalingam, B., Clarke, K., Long, G. V., & Hong, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.007 · Cited by 106
Self-citationGastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management
Grover, S., Rahma, O. E., Hashemi, N., & Lim, R. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100013 · Cited by 106
Cardiorenal complications of immune checkpoint inhibitors
Sury, K., Perazella, M. A., & Shirali, A. C. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0035-1 · Cited by 106
Metadata
- Authors
- Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Arance, A., Schmidt, H., Schadendorf, D., Gogas, H., Lundgren-Eriksson, L., Horak, C., Sharkey, B., Waxman, I. M., Atkinson, V., & Ascierto, P. A.
- Affiliations
- Inserm (FR)
- The University of Sydney (AU)
- Cabrini Hospital (AU)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- University of Siena (IT)
- Hôpital Claude Huriez (FR)
- University Hospital Heidelberg (DE)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Royal Prince Alfred Hospital (AU)
- The authors' affiliations are listed in the Appendix.
- BC Cancer Agency (CA)
- Helsinki University Hospital (FI)
- Royal Victoria Hospital (CA)
- Centrum für Integrierte Onkologie (DE)
- Instituto Nazionale Tumori Regina Elena (IT)
- Hospital Clínic de Barcelona (ES)
- Aarhus University Hospital (DK)
- University of Duisburg-Essen (DE)
- National and Kapodistrian University of Athens (GR)
- Bristol-Myers Squibb (United States) (US)
- Greenslopes Private Hospital (AU)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- ORCID
- Robert, Caroline
- Long, Georgina V.
- Dutriaux, Caroline
- Maio, Michele
- Mortier, Laurent
- Hassel, Jessica C.
- Rutkowski, Piotr
- McNeil, Catriona
- Savage, Kerry J.
- Hernberg, Micaela M.
- Charles, Julie
- Mihalcioiu, Catalin
- Mauch, Cornelia
- Cognetti, Francesco
- Arance, Ana
- Schmidt, Henrik
- Schadendorf, Dirk
- Gogas, Helen
- Atkinson, Victoria
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-22
- Volume
- 372
- Issue
- 4
- Pages
- 320-330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2128035403
- Semantic Scholar
- 6a8a53c7f9fd79ff959c6101698e58d58ff6123e
- Cited by
- 5,519
- References
- 25
- Citations by year
- 2026: 154 · 2025: 230 · 2024: 293 · 2023: 335 · 2022: 430 · 2021: 516 · 2020: 601 · 2019: 586 · 2018: 642 · 2017: 715 · 2016: 614 · 2015: 373
- FWCI
- 274.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, metastatic melanoma, BRAF wild-type melanoma, dacarbazine, immune checkpoint inhibitors, PD-1 inhibitors, overall survival, progression-free survival, objective response rate, PD-L1 expression, treatment-naive patients, adverse events, immunotherapy versus chemotherapy, subgroup analysis
- MeSH terms
- Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Dacarbazine, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Survival Rate, Disease-Free Survival, Proto-Oncogene Proteins B-raf, Young Adult, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
